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PURPOSE. To estimate and compare the change in iris cross-sectional area (IA) and iris volume
(IV) following physiologic and pharmacologic pupil dilation in primary angle closure suspects
(PACS) and normal subjects.
METHODS. Anterior segment–optical coherence tomography (AS-OCT) measurements in light,
dark, and following pharmacologic dilation were obtained on 186 PACS and 224 normal
subjects examined during the 5-year follow-up of the Handan Eye Study. Iris cross-sectional
area, IV, and other biometric parameters calculated using the Zhongshan angle assessment
program in the right eyes of all subjects were analyzed.
RESULTS. The mean IA and IV decreased in dark compared with light and after pharmacologic
dilation in both PACS and normal eyes. This change was statistically significant in normal eyes:
light versus pharmacologic dilation for IA (P ¼ 0.038) and for IV, both light versus dark (P ¼
0.031) and light versus pharmacologic dilation (P ¼ 0.012). A longer axial length (P ¼ 0.028)
and a greater change in pupil diameter (PD) (P < 0.001) were associated with a larger
decrease of IA for the light to dark comparison. A diagnosis of normal eyes (P ¼ 0.011), larger
PD in dark (P ¼ 0.001), and a larger change in PD (P ¼ 0.001) were associated with a larger
decrease of IV from light to dark.
CONCLUSIONS. The differences in iris behavior between PACS and normal rural Chinese subjects
following physiologic or pharmacologic pupillary dilation may help provide insights into the
pathogenesis of angle closure.
Keywords: primary angle closure suspect, anterior segment–optical coherence tomography,
iris volume change, iris cross-sectional area change, mydriasis
Primary angle-closure glaucoma (PACG) is one of the leadingcauses of blindness, and Asians comprise 87% of PACG
patients worldwide.1 Although more people are affected by
POAG than PACG, the proportion of those who suffer serious
loss of vision is considerably higher in PACG and is responsible
for the vast majority (91%) of bilateral glaucoma blindness in
China.1,2
Previously identified ocular risk factors that predispose
individuals to angle closure, include small eyes, shallow central
anterior chamber depth (ACD), short axial length (AL), thicker
and more anteriorly positioned lens, and lens vault.3–7 A
shallow ACD is regarded as a cardinal risk factor for angle
closure, but data from population-based studies suggest that
only a small proportion of those with shallow ACD ultimately
develop PACG.8–10 There are conflicting reports on the
importance of AL and lens position in angle closure.3,5,11
Asians, particularly Chinese and Mongolians, have a substan-
tially greater risk for angle closure than Europeans and Africans
but do not seem to differ in the distribution of their AL or
ACD.11–14 The understanding of which small eyes might
develop angle closure could lie not just in the static anatomy
but in the dynamic responses as well.15
Recent reports support the concept that PACG is a
multifactorial disease caused by a combination of factors both
anatomic and dynamic.6,7,16 While anatomic factors have been
extensively investigated, the dynamic elements and their role is
less clear.17–21 Analysis of such dynamic iris behavior may
provide clues for the higher prevalence of PACG among
Asians.17 Quigley et al.17 hypothesized that the high fluid
content of iris stroma combined with a change in the capacity
for fluid movement could alter iris volume as the pupil dilates,
creating a dynamic factor that could predispose some small
eyes to angle closure. They report that a smaller iris cross-
sectional area (IA) change after pupil dilation could be a
potential risk factor for angle closure in those with European
ancestry.17 They also postulate that a lower decrease in iris
volume (IV) with dilation may present a higher risk of angle
closure.17 A reduction in the transfer of extracellular fluid from
the iris stroma to the anterior chamber was proposed as a
mechanism to explain this anatomic change. In French patients,
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Aptel and Denis18 demonstrated that the IV, as estimated with
anterior segment–optical coherence tomography (AS-OCT),
increased after pupil dilation in narrow-angle eyes predisposed
to acute angle closure. They also found that this biometric
change was associated with angle narrowing, despite a patent
laser peripheral iridotomy (LPI) and that the decrease in IV was
associated with a change to a larger pupil.18 In South Indians,
Ganeshrao et al.19 report that IA and IV decrease as the pupil
dilates in normal and angle-closure eyes; the loss of IV was
lower in angle-closure eyes.
The objective of this study was 2-fold: (1) quantify changes
in IA and IV induced by physiologic and pharmacologic
mydriasis and detect any differences between primary angle
closure suspects (PACS) and normal controls; and (2) assess
whether these changes are associated with demographic and
previously reported ocular biometric measurements.
METHODS
Subjects and Ophthalmic Examination
This observational, cross-sectional study was based on the 5-
year follow-up of the Handan Eye Study (HES). The Handan Eye
Study was conducted on a sample of rural Chinese adults aged
30 years or older living in Handan County, Hebei Province.22
From May 2012 to June 2013, surviving members of the
original HES cohort were reexamined for the 5-year follow-up.
Handan Eye Study subjects aged ‡40 years who participated in
this follow-up examination between September 2012 and
March 2013 and underwent gonioscopy were eligible for
inclusion. Gonioscopy was performed on all subjects with a
peripheral limbal anterior chamber depth (LACD)  40% of
peripheral corneal thickness (CT) as well as for one in 10
subjects (No. 1, 11, 21, etc.) registered per day.
Subjects with peripheral anterior synechiae (PAS), raised
IOP, cup-disc ratio ‡ 0.6/presence of typical glaucomatous
optic neuropathy/field defects, previous intraocular surgery,
previous penetrating eye injury or corneal disorders preventing
anterior chamber assessment, and persons taking antiglaucoma
eyedrops were excluded, as were those who had suffered an
episode of acute angle closure (AAC) attack or had undergone
LPI or laser iridoplasty. Eyes with an episode of AAC attack
were not included because consecutive iris atrophy and
sphincter action loss would distort the analysis of IA and IV.
Eyes with LPI were excluded as they would affect the dynamic
response of the iris to pupil dilation. Also, subjects who were
on topical or systemic medication that could affect the iris or
angle configuration at the time of the study (cholinergics or
anticholinergics, adrenergic agonists or antagonists, serotonin,
norepinephrine, and dopamine releasers, their precursors or
reuptake inhibitors, monoamine oxidase inhibitors; opioid
agonists or antagonists and histamine-receptor antagonists)
were excluded. Those included were divided into PACS and
control groups. Primary angle closure suspects were defined
based on the International Society of Geographical and
Epidemiological Ophthalmology (ISGEO) classification, as eyes
in which the posterior trabecular meshwork was not visible for
at least 1808 on static gonioscopy without PAS on indentation/
manipulation, IOP  21 mm Hg, healthy optic nerves, and
normal visual fields.23 The control group comprised age and
sex, comparable normal subjects (defined as IOP  21 mm Hg
with open angles, healthy optic nerves, and normal visual
fields, no previous surgery, and no family history of glaucoma).
All participants underwent a comprehensive ophthalmic
examination including presenting visual acuity (PVA) and best
corrected visual acuity (BCVA), using the Early Treatment
Diabetic Retinopathy Study (EDTRS) logMAR E chart, objective
and subjective refraction, slit-lamp biomicroscopy, visual field
examination, IOP measurement, gonioscopy, A-scan ultrasound
biometry, and fundus examination. Refraction was measured
using a KR-8800 auto kerato-refractometer (Topcon, Tokyo,
Japan), visual field test using the standard 24-2 Swedish
Interactive Testing Algorithm (SITA) standard program on a
visual field analyzer (Humphrey Visual Field Analyzer 740i or
750i; Carl Zeiss, Jena, Germany), and A-scan ultrasound
biometry using an OcuScan RxP (Alcon, Inc., Fort Worth, TX,
USA). Static gonioscopy was performed at high magnification
(325) with the eye in the primary gaze position using a
Goldmann-type one-mirror lens under the lowest level of
ambient illumination that permitted a view of the angle.
Dynamic examination (manipulation) was then performed
using the same lens. Gonioscopy was performed by one of two
observers (ZP and YSH) who were masked to AS-OCT findings.
The two observers attained a j of 0.76 for assessment of
occludable angle in 30 eyes (not included in this study).
The study was approved by the Beijing Tongren Hospital
Ethics Committee and performed in accordance with the
tenets of the Declaration of Helsinki. All subjects provided
verbal and written informed consent.
AS-OCT Imaging
Anterior segment–optical coherence tomography uses an
infrared light with a wavelength of 1310 nm that optimizes
anterior chamber angle imaging in the absence of visible light
spectrum influence on angle configuration and pupil size.24,25
This technique enables cross-sectional images of the anterior
segment of the eye and is capable of recording transient and
dynamic changes of the pupil at low levels of illumination.24,25
Each eye was imaged with an AS-OCT (Visante; Carl Zeiss
Meditec, Inc., Dublin, CA, USA), first under dark conditions
(approximately 3 lux, to induce physiologic mydriasis), then
with light (approximately 200 lux), and finally 30 minutes after
pharmacologic dilation with tropicamide 1% eyedrops. Since
PACS eyes have a risk of AAC post dilation, the protocol
incorporated precautions to recognize and manage such
events. Subjects recording a normal IOP (<21 mm Hg) at least
1 hour after dilation were allowed to leave. Those with an IOP
of ‡21 mm Hg received IOP-lowering medications as required.
The protocol required those with raised IOP at high risk for an
acute event to stay in the central clinic for one night for further
observation and management. Doctors in the surrounding
towns and villages were made aware of the symptoms that
required patients to be sent back to the clinic.
All images were obtained in the ‘‘anterior segment
quadrant’’ mode at 08 to 1808, 458 to 2258, 908 to 2708, and
1358 to 3158 meridians. For image acquisition of the anterior
chamber angle at 6 and 12 o’clock, the operator gently
retracted the upper and lower lids as needed taking care to
avoid inadvertent pressure on the globe. Imaging was repeated
if the scleral spur visibility was poor, and the best set of images
were selected. In order to obtain images in a nonaccommo-
dated state, the subject’s refractive correction was used to
adjust the internal fixation target for their distance correction.
Custom software (Zhongshan Angle Assessment Program
[ZAAP], Guangzhou, China) was used to calculate IA and IV
after the scleral spur was marked on each side of the image.26
Angle and anterior chamber configuration, including angle-
opening distance at 500 lm (AOD500), trabecular–iris space at
500 lm (TISA500), angle recess area (ARA), ACD, anterior
chamber area (ACA), anterior chamber volume (ACV), anterior
chamber width (ACW), and pupil diameter (PD) were also
analyzed with the same software. Angle opening distance at
500 lm is the distance from the corneal endothelium to the iris
surface as determined from a perpendicular to a line drawn at
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500 lm from the scleral spur.27 Trabecular–iris space at 500
lm is the area bounded anteriorly by the AOD500 as
determined posteriorly by a line drawn from the scleral spur
perpendicular to the plane of the inner scleral wall to the iris,
superiorly by the inner corneoscleral wall, and inferiorly by the
iris surface.28 Angle recess area is the area bordered by the
anterior iris surface, corneal endothelium, and a line perpen-
dicular to the corneal endothelium drawn to the iris surface
from a point at 750 lm anterior to the scleral spur.29
Statistical Analysis
The IA, IV, and PD values represented the average of
measurements from eight iris cross-sections as obtained from
AS-OCT scans; the terms IA and IV are used to designate these
average values. Only the right eye of each subject was included
for analysis. The one-sample Kolmogorov-Smirnov test was
used to assess normality of the measurements. Independent
sample t-tests were used to compare differences between
normal and PACS eyes. The v2 test was used for the analysis of
qualitative variables. Pearson correlation coefficient or (where
indicated) partial correlation coefficient was used to assess the
relationship between IA or IV and PD. Linear regression
analysis was used to analyze factors associated with IA and IV
change (from light to dark). Univariable regression was
conducted with changes in IA and IV as the dependent
variable and the effects of age, sex, central corneal thickness
(CCT), ACD, lens thickness (LT), AL, PD in light, PD in dark, PD
change, and diagnosis (PACS or normal) as predictors. Variables
that were significant at a level of P < 0.2 were included in a
multivariable linear regression model. As this was an explan-
atory rather than a predictive study, we were prepared to be
more inclusive and incorporate variables based on previous
reports as well as biologic plausibility. The SPSS statistical
software (Version 17.0; SPSS, Inc., Chicago, IL, USA) was used
for data analysis. Statistical significance was set at P < 0.05.
RESULTS
Subjects Characteristics
A total of 485 subjects attending the 5-year HES follow-up were
eligible for inclusion. Forty-five eyes (19.5%) in the PACS group
and 30 eyes (11.8%) in the normal group were excluded owing
to poor image quality and inability to accurately identify the
scleral spur. Accordingly, 410 eyes of 410 subjects, including
186 PACS eyes and 224 normal eyes were available for analysis.
None of the patients had an episode of AAC on dilation.
The demographic data and ocular biometric measurements
are shown in Table 1. Primary angle closure suspects had
worse PVA (P¼ 0.007), lower IOP (P¼ 0.043), shallower ACD
(P < 0.001), and shorter AL (P < 0.001) than normal subjects.
The mean values for AS-OCT parameters and PD of normal and
PACS eyes in light, dark, and after pharmacologic dilation along
with the differences between the two groups are shown in
Tables 2, 3, and 4. The mean values for AOD500, TISA500,
ARA, ACD, ACW, ACA, and ACV were significantly lower in the
TABLE 1. Demographic and Biometric Characteristics
Parameter PACS Subjects, n ¼ 186 Healthy Subjects, n ¼ 224 Total Subjects, n ¼ 410 P Value
Age, y (SD) 60.5 (8.4) 59.3 (7.4) 59.8 (7.9) 0.110*
Male (%) 66 (32.3) 94 (42.0) 160 (39.0) 0.188†
Female (%) 120 (64.5) 130 (58.0) 250 (61.0)
PVA (IR) 0.30 (0.10, 0.50) 0.20 (0.10, 0.30) 0.20 (0.10, 0.40) 0.007‡
BCVA (IR) 0.00 (0.00, 0.20) 0.00 (0.00, 0.10) 0.00 (0.00, 0.16) 0.085‡
SE (IR) 0.00 (0.00, 1.13) 0.00 (0.00, 0.75) 0.00 (0.00, 0.88) 0.143‡
IOP (IR) 12.0 (10.5, 13.0) 12.5 (11.0, 14.0) 12.0 (11.0, 14.0) 0.043‡
CCT (IR) 528 (516, 548) 531 (517, 547) 530 (516, 547) 0.703‡
Central ACD (IR) 2.49 (2.31, 2.77) 2.73 (2.51, 2.89) 2.62 (2.40, 2.86) <0.001‡
LT (IR) 4.84 (4.54, 5.10) 4.81 (4.49, 5.05) 4.83 (4.51, 5.06) 0.330‡
AL (SD) 22.33 (0.81) 22.74 (0.73) 22.56 (0.79) <0.001*
IR, interquartile range; SE, spherical equivalent.
* Independent t-test.
† v2 test.
‡ Mann-Whitney test.
TABLE 2. AS-OCT in Light
Parameter PACS Subjects, n ¼ 186 Healthy Subjects, n ¼ 224 Total Subjects, n ¼ 410 P Value
AOD500, mm (SD) 0.255 (0.103) 0.333 (0.096) 0.298 (0.107) <0.001*
TISA500, mm2 (IR) 0.103 (0.078, 0.136) 0.132 (0.113, 0.164) 0.123 (0.096, 0.151) <0.001†
ARA500, mm2 (SD) 0.263 (0.099) 0.367 (0.100) 0.320 (0.112) <0.001*
IA, mm2 (SD) 2.90 (0.36) 2.94 (0.35) 2.92 (0.35) 0.315*
IV, mm3 (SD) 28.97 (3.83) 29.46 (3.02) 29.24 (3.42) 0.150*
ACD, mm (SD) 2.276 (0.244) 2.461 (0.222) 2.377 (0.250) <0.001*
ACW, mm (SD) 10.90 (0.41) 11.12 (0.37) 11.02 (0.40) <0.001*
ACA, mm2(SD) 16.13 (2.39) 18.10 (2.33) 17.21 (2.55) <0.001*
ACV, mm3 (SD) 62.61 (12.02) 73.37 (12.33) 68.49 (13.31) <0.001*
PD, mm (SD) 3.99 (0.65) 4.03 (0.64) 4.01 (0.64) 0.529*
IR, interquartile range.
* Independent t-test.
† Mann-Whitney test.
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PACS group in all three conditions (P  0.001). Variables
demonstrating a normal distribution are presented as mean
(SD), while variables failing to achieve a normal distribution are
presented as median (percentiles).
Iris Cross-Sectional Area and Iris Volume
Measurements
A summary of mean IAs and IVs from eyes of PACS and normal
subjects as measured in light, dark, and after dilation is
presented in Tables 2, 3, and 4.
Table 5 summarizes changes in IA, IV, and PD in the two
groups between light and dark, light and pharmacologic
dilation, and dark to pharmacologic dilation. The smaller
changes in IA for PACS versus normal eyes were statistically
significant for the light to pharmacologic dilation comparison
(P¼ 0.038). The smaller changes in IV for PACS versus normal
eyes were statistically significant for both light to dark (P ¼
0.031) and light to pharmacologic dilation comparisons (P ¼
0.012).
Iris cross-sectional area and IV decreased with increasing
PD over the whole range (light, dark, and after pharmacologic
dilation) in both groups (Figs. 1, 2). Pearson correlation
coefficients for IA and PD were 0.885 for normal eyes and
0.853 for PACS eyes. Partial correlation coefficients between
IV and PD were 0.761 for normal eyes and 0.640 for PACS
eyes.
Results of univariable and multivariable linear regression
analysis of IA and IV change from light to dark are shown in
Tables 6 and 7. Longer AL (P¼ 0.028) and larger PD changes (P
< 0.001) were associated with greater decrease in IA.
Normal eyes showed greater decrease in IV (P ¼ 0.011).
Following physiologic dilation in the dark, larger PD was
associated with greater decrease in IV (P¼0.001), as was larger
change in PD (P ¼ 0.001).
Both PACS as well as normal eyes had lower IA and IV
measurements with pharmacologic compared with physiologic
dilation and changes in these parameters were also larger with
pharmacologic dilation. Change in PD was greater with
pharmacologic dilation.
DISCUSSION
There are multiple factors that predispose to angle closure; a
population-based study reported that only 22% of PACS
progressed to primary angle closure (PAC) in 5 years.30 Clearly,
the mechanism through which PACS progresses to PAC is
poorly understood.16,31 We are beginning to recognize that
primary angle closure disease (PACD) likely results from an
interaction of multiple anatomic factors (that cause narrow
angles in different combinations), as well as many dynamic
elements.16,20,32,33 It has also been suggested that the latter
may play more of a role in AAC.16
Previous studies have hypothesized that change in the
volume of the iris with pupillary dilation is a dynamic factor
that could predispose some anatomically susceptible eyes to
PACD.17–19,34–37 The limited number of subjects included in
these seminal studies is a limitation and makes it difficult to
draw robust conclusions.
The 5-year follow-up of the population-based HES provided
an opportunity to collect data for change in iris with pupillary
dilation. To the best of our knowledge, this is the first study
investigating the role of dynamic iris changes in PACS in a rural
Chinese population. The sample was not strictly population
based, but participants were no different from others enrolled
in the HES and provided measurements in a large number of
PACS and normal subjects.
Iris cross-sectional area and IV decreased both in PACS and
normal eyes after both physiologic and pharmacologic dilation.
TABLE 3. AS-OCT in Dark
Parameter PACS Subjects, n ¼ 186 Healthy Subjects, n ¼ 224 Total Subjects, n ¼ 410 P Value*
AOD500, mm (SD) 0.252 (0.106) 0.322 (0.100) 0.290 (0.108) <0.001
TISA500, mm2 (SD) 0.102 (0.040) 0.131 (0.039) 0.117 (0.042) <0.001
ARA500, mm2 (SD) 0.248 (0.099) 0.334 (0.102) 0.295 (0.109) <0.001
IA, mm2 (SD) 2.70 (0.37) 2.70 (0.32) 2.70 (0.35) 0.787
IV, mm3 (SD) 28.28 (4.13) 28.53 (3.21) 28.41 (3.65) 0.496
ACD, mm (SD) 2.285 (0.264) 2.457 (0.224) 2.379 (0.257) <0.001
ACW, mm (SD) 10.89 (0.43) 11.09 (0.35) 11.00 (0.40) <0.001
ACA, mm2 (SD) 16.60 (2.53) 18.49 (2.33) 17.63 (2.60) <0.001
ACV, mm3 (SD) 64.65 (12.61) 74.83 (12.29) 70.21 (13.42) <0.001
PD, mm (SD) 4.71 (0.70) 4.78 (0.64) 4.75 (0.67) 0.244
* Independent t-test.
TABLE 4. AS-OCT After Pharmacologic Dilation
Parameter PACS Subjects, n ¼ 186 Healthy Subjects, n ¼ 224 Total Subjects, n ¼ 410 P Value*
AOD500, mm (SD) 0.236 (0.094) 0.386 (0.100) 0.318 (0.122) <0.001
TISA500, mm2 (SD) 0.094 (0.032) 0.149 (0.034) 0.124 (0.043) <0.001
ARA500, mm2 (SD) 0.269 (0.106) 0.425 (0.121) 0.354 (0.138) <0.001
IA, mm2 (SD) 1.80 (0.31) 1.77 (0.26) 1.79 (0.28) 0.357
IV, mm3 (SD) 21.45 (3.33) 21.40 (2.88) 21.42 (3.09) 0.886
ACD, mm (SD) 2.358 (0.265) 2.546 (0.243) 2.461 (0.270) <0.001
ACW, mm (SD) 11.12 (0.41) 11.25 (0.37) 11.19 (0.39) 0.001
ACA, mm2 (SD) 19.54 (2.73) 21.56 (2.44) 20.64 (2.76) <0.001
ACV, mm3 (SD) 84.42 (14.78) 95.32 (13.32) 90.37 (15.01) <0.001
PD, mm (SD) 7.15 (0.63) 7.26 (0.53) 7.21 (0.58) 0.058
* Independent t-test.
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Pupil diameter and IV showed a negative correlation. This
would support the hypotheses that losses in IV with increasing
PD occur by transfer of fluid into the anterior chamber by
transfer of aqueous through macroscopic and microscopic
channels into and out of the iris stoma.17
The decrease of IA after physiologic and pharmacologic
dilation was less in PACS than normal eyes but was statistically
significant only for the light to pharmacologic dilation
comparison, which is a larger change in pupillary diameter.
Iris volume was also found to decrease less in PACS eyes. The
differences in IV between PACS and normal eyes were
statistically significant for light to dark and for light to
pharmacologic dilation comparisons, but not for the dark to
pharmacologic dilation measurements. Ganeshrao et al.19 and
Aptel et al.35 reported a similar change in IA and IV with
pupillary dilation between light and dark. Accordingly, the lack
of statistical significance should not detract from the hypoth-
esis that this change reflects transfer of fluid from the iris
stroma with pupil dilation. Eyes with more compact or water-
retentive stroma would lose less fluid and retain more volume.
It is possible that the IOP elevation that occurs with iris
apposition and results in PAC/PACG is limited to a subset of
irides with the poorest fluid conductivity; the factors required
to cause AAC may be different from that of asymptomatic
disease.16 Our results reiterate that the dynamic behavior of
the iris is one of the component causes in sufficient
component causal models for PACD.
In all eyes, less IA decrease was associated with a shorter AL
and a smaller PD change. Moreover, the degree of IV reduction
was less in PACS eyes, shallower ACD, smaller PD (in dark), and
FIGURE 1. Pupillary diameter versus iris cross-sectional area.
TABLE 5. Changes in Iris Area, Iris Volume, and Pupillary Diameter
Parameter PACS Subjects, n ¼ 186 Healthy Subjects, n ¼ 224 Total Subjects, n ¼ 410 P Value*
L to D
IA change, mm2 (SD) 0.21 (0.21) 0.23 (0.19) 0.22 (0.20) 0.191
IV change, mm3 (SD) 0.70 (2.24) 1.15 (2.03) 0.95 (2.14) 0.031
PD change, mm (SD) 0.72 (0.42) 0.76 (0.41) 0.74 (0.41) 0.367
L to P
IA change, mm2 (SD) 1.10 (0.29) 1.17 (0.30) 1.14 (0.30) 0.038
IV change, mm3 (SD) 7.53 (3.11) 8.28 (2.88) 7.94 (3.00) 0.012
PD change, mm (SD) 3.17 (0.72) 3.24 (0.67) 3.21 (0.69) 0.317
D to P
IA change, mm2 (SD) 0.90 (0.28) 0.93 (0.26) 0.92 (0.27) 0.185
IV change, mm3 (SD) 6.83 (3.20) 7.12 (2.77) 6.99 (2.97) 0.323
PD change, mm (SD) 2.45 (0.65) 2.48 (0.60) 2.47 (0.63) 0.609
L to D, light to dark; L to P, light to after pharmacologic dilation; D to P, dark to after pharmacologic dilation.
* Independent t-test.
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smaller PD change. All these findings make biological sense
and provide further support for the hypothesis that a
diminished tendency to lose IV with dilation contributes to
PACD. We suggest that PACS eyes, which display extreme or
unusual iris responses may be more likely to close in darkness
and predispose to PACD. We accept that ‘‘extreme’’ or
‘‘unusual’’ could be different for anatomically different eyes
and remain to be identified with further research.16 In
multifactorial disorders like PAC and PACG, all patients do
not share the exact same set of risk factors, and this may be
more complex in some ethnicities like the Chinese who seem
to have multiple mechanisms of angle closure. Perhaps
differences in the amount of physiologic mydriasis in the dark
play a role. That the role of IV change in progression to PAC
may vary between patients, and more broadly between
ethnicities, is compatible with the sufficient component causal
model for multifactorial diseases.16,38 A smaller change of IV
with dilation is likely contributory to progression only in a
subset of PACS that also have a critical anatomic predisposition,
and the components involved in AAC are likely different from
that of asymptomatic disease. Longitudinal prospective studies
are needed to investigate the risk of an IV change in predicting
the development of PAC and PACG in those with varying
degrees of anatomic risk factors.
There is a weakness in our study. The study is not strictly
population based. However, there were no significant differ-
ences in the characteristics of PACS and normal subjects
between our study sample and the larger HES cohort.39
In summary, our study showed that despite similar
baselines, PACS and normal eyes from a rural Chinese
population respond differently to both physiologic and
pharmacologic pupillary dilation. Such differences in iris
TABLE 6. Factors Associated With IA Change (Light to Dark)
Variable
Univariable Multivariable
b P Value Direction b P Value
Age 0.117 0.018 0.001 0.977
Sex 0.018 0.723 - -
SE 0.098 0.047 0.041 0.279
CCT 0.006 0.905 - -
ACD 0.099 0.048 0.025 0.534
LT 0.018 0.724 - -
AL 0.120 0.016 Eyes with longer AL had more
IA change
0.082 0.028
PACS vs. normal 0.065 0.191 0.019 0.614
PD; L 0.150 0.002 0.012 0.760
PD; D 0.270 <0.001 0.012 0.760
PD change; L to D 0.667 <0.001 Eyes with larger PD change (L to D)
had more IA change
0.664 <0.001
FIGURE 2. Pupillary diameter versus iris volume.
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behavior may partly explain why only a small proportion of
narrow-angle eyes develop PACD. Longitudinal studies will be
required to assess the hypothesis that IV change may identify
PACS that are at a higher risk of PACD, thereby identifying
those who may benefit from an iridotomy.
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